Last reviewed · How we verify
Semaglutide Oral Product
Semaglutide Oral Product is a Small molecule drug developed by Imperial College London. It is currently in Phase 1 development.
At a glance
| Generic name | Semaglutide Oral Product |
|---|---|
| Sponsor | Imperial College London |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes (NA)
- Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss. (PHASE2)
- Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NA)
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America (PHASE4)
- Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study (PHASE4)
- Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Semaglutide Oral Product CI brief — competitive landscape report
- Semaglutide Oral Product updates RSS · CI watch RSS
- Imperial College London portfolio CI
Frequently asked questions about Semaglutide Oral Product
What is Semaglutide Oral Product?
Semaglutide Oral Product is a Small molecule drug developed by Imperial College London.
Who makes Semaglutide Oral Product?
Semaglutide Oral Product is developed by Imperial College London (see full Imperial College London pipeline at /company/imperial-college-london).
What development phase is Semaglutide Oral Product in?
Semaglutide Oral Product is in Phase 1.
Related
- Manufacturer: Imperial College London — full pipeline
- Compare: Semaglutide Oral Product vs similar drugs
- Pricing: Semaglutide Oral Product cost, discount & access